kidney cancer

Renal cancer follow-up: Find the happy mediumNurse practitioner Adele M. Caruso, MSN, CRNP, discusses appropriate timing of follow-up and ponders related health insurance coverage and cancer survivorship issues.
Renal biopsy may alter management in high-risk patientsIn this interview, E. Jason Abel, MD, discusses biopsy’s role in small and large renal masses, associated risks, and when patients can be safely observed.
Study appears to refute obesity paradox in kidney cancerIn this interview Mark A. Preston, MD, MPH, of Brigham and Women’s hospital sat down with Richard. R. Kerr, Urology Times content channel director, to discuss the association between obesity and incidence of total and fatal renal cell carcinoma in two prospective cohorts. The interview was conducted during the AUA annual meeting in New Orleans.
Opdivo approved for patients with metastatic renal cell carcinomaFDA approved nivolumab (Opdivo, Bristol-Myers Squibb) for the treatment of patients with metastatic renal cell carcinoma.
Uro Pipeline: IDE approval granted for implantable neurostimulatorA prostate cancer vaccine and an infertility diagnostic tool are among the other pipeline products discussed in this round-up.
RCC trials don’t mirror real-world experienceStudy findings point to “a concept that has haunted clinical trialists for years,” says one expert.
Immunotherapy shows survival benefit in advanced RCCAn immune checkpoint inhibitor provides “a real opportunity to change clinical practice” for patients with metastatic renal cell carcinoma, a study author says.
Best of AUA 2015: PCa surveillance, surgical controversies create buzzUrology Times’ “Best of AUA 2015” report provides a guide to the meeting’s take-home messages in 15 therapeutic areas—an information-packed, condensed summary of the top papers and presentations.
Metastatic RCC: High-dose IL-2 ups overall survivalThe survival benefit associated with high-dose IL-2 in metastatic renal cell carcinoma may be better than previously believed.
Selective clamping promising in robot-assisted PNNear-infrared fluorescence-guided selective clamping with indocyanine green fluorescent dye in robot-assisted partial nephrectomy appears to be a promising technique to delineate renal tumor anatomy for the bloodless resection of renal masses while minimizing ischemic damage to the kidney.